Thyroid function, HbA1c, fasting glucose, cholesterol, and liver enzymes are all affected by the menopause transition, and all can influence both eligibility and response to treatment
Rarely does it land in a blood vessel, but it is always best to be safe rather than sorry prior to injecting
A 48-week Phase 2 trial reported in The Lancet in 2025 showed mean weight reduction ranging from approximately 9% at the lowest dose to 20% at the highest dose, compared with 0.4% on placebo
It has demonstrated potential in influencing prostate health by promoting tissue repair and reducing inflammation
GLP-1s are not by any means the only habit catalyst
Bioactive compounds and advanced processing technology: Phaleria macrocarpa (Scheff.) Boerl, a review